Board &
Management
Mark Davies
Chairman
BCom
Mark Davies has more than 20 years’ experience in trading, investment banking & providing corporate advice. Mark specialises in providing corporate advice & capital raising services to emerging companies seeking business development opportunities and funding from the Australian market. Mark is the Managing Director of 1861 Capital and co-founder of investment banking firm, Cygnet Capital.
Dr Anthony Filippis
Managing Director & CEO
BSc (Hons.), PhD, MBA
Dr Anthony Filippis is a seasoned executive with over 25 years of leadership experience across the biotechnology, healthcare, and investment sectors. His expertise spans multiple therapeutic areas, including neuroscience, oncology, and endocrinology, with a particular focus on commercialising innovative clinical therapeutics for diseases with high unmet medical need.
Over the course of his career, Anthony has held senior roles at several ASX-listed and private life sciences companies. He has a proven track record in driving strategic partnerships, securing capital to advance clinical programs, and leading negotiations for in- and out-licensing agreements, as well as mergers and acquisitions.
In addition to his PhD, Anthony holds an MBA and actively contributes to the industry through his roles on various boards and committees, as well as mentoring emerging leaders.
Robert Maxwell Johnston
Non-Executive Director
Robert Maxwell Johnston held the position of President and Chief Executive officer of Johnson and Johnson Pacific, a division of the world’s largest healthcare company for 11 years. Robert’s career also included senior roles within Australia and overseas with Unilever and Guinness-United Distillers and several prominent industry body roles as past President of ACCORD Australasia Limited, Vice Chairman of AFGC, and Board Member of ASMI.
Robert is currently a Non-executive Director of Inoviq Ltd (ASX: IIQ) and was a former Non-executive director of PolyNovo Ltd (ASX: PNV), Medical Developments International Limited (ASX: MVP), Tissue Repair Ltd (ASX: TRP), Enero Group Limited (ASX: EGG), Non-executive Chairman of Probiotec Ltd (ASX: PBP), Non-executive Chairman of AusCann Pty Ltd (ASX: AC8). He also acted as interim CEO of PolyNovo from November 2021 to August 2022.
Gerald Quigley
Director of Public Relations
B(Pharm)
Gerald is a qualified Pharmacist and a consumer health commentator. Gerald is a leading media health commentator heard each week on television and radio stations across Australia. Gerald has extensive knowledge relating to pharmaceutical/ nutraceutical product development, dispensing & marketing in addition to product positioning within the relevant regulatory landscapes (eg. TGA, FDA).